1 active not recruiting, 1 recruiting. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Recruiting 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow CYH33: new trials by email Literature Review of CYH33 trials Research Report on CYH33
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Patients With PIK3CA-related Overgrowth Spectrum (PROS) and PIK3CA-related Vascular Malformations (PRVM) CYH33, Placebo - PIK3CA-Related Overgrowth Spectrum (PROS), PIK3CA-related Vascular Malformations (PRVM) | Phase 1 / Phase 2 | Recruiting | Haihe Biopharma Co., Ltd. | 141 | 2023-08-22 | 2026-06-29 |
| A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma CYH33 - Ovarian Cancer, Recurrent Cancer | Phase 2 | Active not recruiting | Haihe Biopharma Co., Ltd. | 93 | 2021-10-11 | 2026-01-30 |
Ovarian Neoplasms (1) · Recurrence (1)
China (2) · Japan (2)